Home Azacitidine Administration in High Risk Myelodysplastic Syndromes: Favorable Results of a Pilot Study in 48 Patients
Sylvestre Guillevic, Odile Beyne‐Rauzy(Université Paris-Sud), D. Adoué, Christian Récher(Institut universitaire du cancer de Toulouse Oncopole), Laurent Guy, Thibault Comont(Institut universitaire du cancer de Toulouse Oncopole), S. Ollier(Institut universitaire du cancer de Toulouse Oncopole), Pierre Cougoul(Hôpital Purpan), Jonathan Khalifa(Inserm)
Cited by 1
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
|The Lancet Oncology|2014|703
Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study
|The Lancet Infectious Diseases|2017|587